Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure.

Luis M Pérez-BelmonteJaime Sanz-CánovasMercedes Millán-GómezJulio Osuna-SánchezAlmudena López-SampaloMichele RicciManuel Jiménez-NavarroMaria D López-CarmonaMaría Rosa Bernal-LópezMiguel A BarbanchoJosé P LaraRicardo Gómez-Huelgas

Published in: Journal of the American Geriatrics Society (2021)

In very old patients with type 2 diabetes hospitalized for acute heart failure, continuing preadmission empagliflozin reduced NT-proBNP levels and increased diuretic response and urine output compared to a basal-bolus insulin regimen. The empagliflozin regimen also showed a good safety profile.

Keyphrases

acute heart failure
heart failure
type diabetes
glycemic control
atrial fibrillation
medical education
metabolic syndrome
insulin resistance